Abstract:Background: Tumor associated macrophages (TAMs) have strong plasticity and if reprogrammed, can clear tumor cells and regulate the adaptive immune system for cancer immunotherapy. Deubiquitinating enzymes (DUBs), which can remove ubiquitin (Ub) from Ub-modified substrates, have been associated with oncogenic metabolism but are not well-known for regulating TAMs repolarization.Methods: The expression of DUB related genes in macrophages (MΦs) was detected by reverse transcription-PCR. Flow cytometry and immunofluorescence were used to detect the changes of immune cells in the tumor microenvironment and spleen, including M1 (CD11b+F4/80+CD86+CD206-), and M2 (CD11b+F4/80+CD86-CD206+) MΦs, and IFN-γ+CD8+T cells. A proliferation assay was used to determine the effect of M2 MΦs treated with a USP7 inhibitor on T cell proliferation. Western blotting was used to detect the expression of USP7 and the activation of the MAPK pathway. The TGCA database was used to assess the role of USP7 in the immune microenvironment of human lung adenocarcinoma (LUAD).Results: 51 DUB genes were screened and USP7 was identified as a highly expressed gene in M2 but not M1 MΦs. Specific silencing of USP7 using siRNA or USP7 inhibitors led to phenotypical and functional changes in M2 MΦs, favoring CD8+T cells proliferation in vitro. USP7 inhibitors delayed tumor growth in mice with Lewis lung carcinoma, and promoted tumor infiltration of M1 MΦs and IFN-γ+CD8+T cells. Depletion of TAMs attenuated these therapeutic effects. USP7 inhibition was shown to mediate MΦs reprogramming by activating the p38 MAPK pathway. Administration of USP7 inhibitors increased the expression of programmed cell death ligand 1 (PD-L1) in tumors, while blocking programmed cell death protein 1 (PD-1) provided an effective anti-tumor response. Clinical databases suggest that high expression of USP7 in LUAD was negatively correlated with innate and adaptive immunity.Conclusions: Taken together, these results provide evidence to suggest that therapeutic approaches targeting USP7, in combination with immunotherapy, should be considered for lung cancer treatment.

CDDO-Me Reveals USP7 As a Novel Target in Ovarian Cancer Cells

Pharmacological USP2 Targeting Suppresses Ovarian Cancer Growth by Potentiating Apoptosis and Ferroptosis

USP7 Inhibits Osteoclastogenesis Via Dual Effects of Attenuating TRAF6/TAK1 Axis and Stimulating STING Signaling

Hsp90 Is A Novel Target Molecule Of Cddo-Me In Inhibiting Proliferation Of Ovarian Cancer Cells

Inhibition of USP7 upregulates USP22 and activates its downstream cancer-related signaling pathways in human cancer cells

Targeting Ubiquitin-Specific Protease 7 (USP7) in Cancer: A New Insight to Overcome Drug Resistance

Identification of the Deubiquitinase USP28 As a Novel Molecular Therapeutic Target of Ovarian Cancer.

Characterization of Naturally Occurring Pentacyclic Triterpenes As Novel Inhibitors of Deubiquitinating Protease USP7 with Anticancer Activity in Vitro

Inhibition of USP21 leads to ovarian carcinoma cell death by suppressing MAPK signaling

Targeting USP7-Mediated Deubiquitination of MDM2/MDMX-p53 Pathway for Cancer Therapy: Are We There Yet?

USP7 Substrates Identified by Proteomics Analysis Reveal the Specificity of USP7.

USP33 facilitates the ovarian cancer progression via deubiquitinating and stabilizing CBX2

USP7 Promotes Cell Proliferation Through the Stabilization of Ki-67 Protein in Non-Small Cell Lung Cancer Cells

USP7 targeting modulates anti-tumor immune response by reprogramming Tumor-associated Macrophages in Lung Cancer

Virtual Screening Inhibitors of Ubiquitin‐specific Protease 7 combining Pharmacophore Modeling and Molecular Docking

Discovery of Ubiquitin-Specific Protease 7 (USP7) Inhibitors with Novel Scaffold Structures by Virtual Screening, Molecular Dynamics Simulation, and Biological Evaluation

Abstract 3939: Inhibition of USP7 upregulates USP22 through desuppression of transcriptional activity of Sp1 in human cancer cells

Design and synthesis of novel mitochondria-targeted CDDO derivatives as potential anti-cancer agents

USP43 impairs cisplatin sensitivity in epithelial ovarian cancer through HDAC2-dependent regulation of Wnt/β-catenin signaling pathway

Virtual screening of natural products targeting ubiquitin-specific protease 7

The emerging nature of Ubiquitin-specific protease 7 (USP7): a new target in cancer therapy